Table 3.
Clinical quality indicators in DAPROCAdata (year 2014)
| Indicator | Description of indicator | Type of indicator | Standarda |
|---|---|---|---|
| Indicator 1: hospital admission after TRUS | Proportion of patients admitted after TRUS-guided biopsy | Process | <5% |
| Indicator 2a: active surveillance after 1 year | Proportion of patients under “active surveillance” without events after 1 year | Process | >70% |
| Indicator 2b: active surveillance after 3 years | Proportion of patients under “active surveillance” without events after 3 years | Process | >50% |
| Indicator 3: positive surgical margin (pT2) | Proportion of RP patients (pT2) with positive surgical margins | Result | <25% |
| Indicator 4: positive surgical margin (pT3) | Proportion of RP patients (pT3) with positive surgical margins | Result | <40% |
| Indicator 5: postoperative morbidity | Proportion of patients with postoperative admission >3 days | Result | <5% |
| Indicator 6: 30-day morbidity | Proportion of patients readmitted with complications <30 days after RP operation | Result | <5% |
| Indicator 7a: 1-year morbidity | Proportion of RP patients with any hospital admission >30 days and <1 year after operation | Result | Not defined |
| Indicator 7b: 1-year morbidity | Proportion of RP patients with any hospital admission >30 days and <1 year after radiation therapy | Result | Not defined |
| Indicator 8: 1-year mortality | Proportion of RP patients deceased <1 year after operation | Result | >1% |
| Indicator 9a: endocrine treatment for T1/T2 | Proportion of patients with T1/T2 disease (<T3; No/Nx; Mo/Mx; PSA<40) receiving endocrine treatment <6 months after diagnosis (M+) | Process | >25% |
| Indicator 9b: endocrine treatment for N1 | Proportion of patients with N1 stage (N1; Mo/Mx/Missing M) receiving endocrine treatment <6 months after diagnosis | Process | >75% |
| Indicator 9c: endocrine treatment for M1 | Proportion of patients with metastases (M1) receiving endocrine treatment <6 months after diagnosis (<T3No; Nx; Mo; Mx; PSA <40) | Process | >75% |
| Indicator 10a: data completeness | Proportion of diagnosed patients with PSA, cardinal symptoms, and cTNM variables registered in the DAPROCA – Diagnosis Clinical Data Registration Form | Result | >90% |
| Indicator 10b: data completeness | Proportion of RP patients with registration of treatment history in the DAPROCA – Urology Clinical Data Registration Form | Result | >80% |
| Indicator 10c: Data completeness | Proportion of patients receiving curative radiotherapy and with a registration of the date of clinical decision making in the DAPROCA – Oncology Clinical Data Registration Form | Result | >90% |
| Indicator 10d: data completeness | Proportion of patients with completed PROM questionnaires | Result | >80% |
Note:
a
Standard =% fulfillment of indicator.
Abbreviations: DAPROCAdata, Danish Prostate Cancer Database; DAPROCA, Danish Prostate Cancer Group; PROM, patient-reported outcome measures; PSA, prostate-specific antigen; RP, radical prostatectomy; TRUS, transrectal ultrasound; TNM, tumor, node, and metastasis cancer stage classification.